Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2019
Price : $35 *
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 19 Mar 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress